Alimera banks $40M; Epizyme snags $4M GSK milestone; Noven claims PhIII success for menopause therapy;

Conversation on Twitter :

 @FierceBiotech: Special report: The Top Phase III Disasters of 2012. Report | Follow @FierceBiotech

 @JohnCFierce: First "complete virtuous circle" for crowdfunding biotech model in France. Interesting idea. Hard to pull off. Release | Follow @JohnCFierce

 @RyanMFierce: Nice to see VentiRx deal with Celgene, and a win for a biotech with small virtual staff and big potential. More | Follow @RyanMFierce

> Alimera Sciences has raised $40 million from the sale of its shares to institutional investors. Report

> Epizyme has earned a $4 million milestone from its partnership with GlaxoSmithKline ($GSK). Release

> The Leukemia and Lymphoma Society and Celgene have agreed to partner on research into new blood cancer treatments. Release

> Noven Pharmaceuticals says it has gathered positive data from its Phase III studies "evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause." Release

Pharma News

@FiercePharma: Novartis drops its legal case against U.K. doc group that nixed Lucentis. The group changed policy after Novartis cut price. More | Follow @FiercePharma

> Private equity's pharma hopes exemplified by Nycomed. More

> Celgene's Abraxane delivers in melanoma study. Article

> Sanofi, Bristol revamp Plavix partnership for post-patent world. Story

> Sanofi buying Genfar as it rolls across Latin America. News

Medical Device News

 @FierceMedDev: Paper Dx could become even cheaper if this new research finding catches on. More | Follow @FierceMedDev

 @MarkHFierce: The U.S. breast implant market will grow modestly in the coming years, Millennium estimates, but Europe's won't. More | Follow @MarkHFierce

 @DamianFierce: Fresh off its $100M IPO, Globus Medical got FDA approval for its spinal disc implant. More | Follow @DamianFierce

> Analysts: Device market growth will outpace pharma by 2018. News

> Allergan abandons pursuit of FDA clearance for teen use of Lap-Band obesity device. Article

Biomarkers News

> Singulex heads for $86.25M flotation. Item

> RNA profiles pinpoint the course of MS. Story

> Biomarkers boost success, cut costs in breast cancer clinical trials. Article

> Singulex heads for $86.25M flotation. More

Drug Delivery News

> Pfizer pays out on Antares drug delivery tech agreement. News

> Nanoparticles getting under your skin? Maybe not, actually. Story

> Noven ADHD patch heads into Phase II. Article

And Finally… Investigators at Texas A&M have been probing into the reason why phobias are so difficult to treat. Story

 

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.